VYNE Therapeutics Q2 2022 net loss $8.5M, improved from $19.9M YoY

VYNE Therapeutics Inc.

2022-Q2 EPS reported -$0.07 revenue$304,000

GAAP loss from continuing operations $8.2M in Q2 2022 vs $10.7M in Q2 2021.
Adjusted net loss (non-GAAP) $7.3M in Q2 2022 vs $18.0M in prior year.
Six-month adjusted net loss $1.8M vs $36.1M in H1 2021, driven by discontinued operations.
CEO highlights BET inhibitor platform potential for immuno-inflammatory diseases.
No revenue reported; company remains in development stage.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.